Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community-acquired respiratory tract infections?

Table 5 Antimicrobial susceptibility of S. aureus as classified by CLSI and EUCAST §

Antimicrobial agent^a(n° of strains)	CLSI susceptibility breakpoint (mg/L)	EUCAST susceptibility breakpoint(mg/L)	CLSI %S	EUCAST %S	Type of discrepancy^b
Teicoplanin (56.399)	≤8	≤2	99.9	98.4	minor
Gentamicin (45.807)	≤4	≤1	93.6	89.1	minor
Amikacin (6.446)	≤16	≤8	97.6	92.6	minor
Tobramycin (3.155)	≤4	≤1	94.7	88.2	minor
Azithromycin (7.223)	≤2	≤1	58.6	56.2	minor
Clarithromycin (7.146)	≤2	≤1	58.8	58.5	-
Erytromycin (36.118)	≤0.5	≤2	74.8	77.4	minor
Tetracycline (1.864)	≤4	≤1	74.6	74.3	-
Doxycycline (5.037)	≤4	≤1	97.6	88.7	minor
Minocycline (1.417)	≤4	≤0.5	99.4	96.9	minor
Clindamycin (25.879)	≤0.5	≤0.25	87.5	87.2	-
Trimethoprim (449)	≤8	≤2	91.5	89.1	minor
Rifampin (1.154)	≤1	≤0.064	96.4	95.0	minor

§ CLSI [11] and EUCAST [13].
^a For Penicillin, Oxacillin, Vancomycin, Daptomycin, Ciprofloxacin, Levofloxacin, Ofloxacin, Moxifloxacin, Chloramphenicol, Trimethoprim-sulfamethoxazole, Quinupristin-dalfopristin and Linezolid CLSI and EUCAST suggested the same susceptibility breakpoints.
^b Discrepancy as defined in the materials and methods section.

ISSN: 1471-2334